![Yannis Morel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 801 410 $ al 30/06/2026
Yannis Morel is currently the Chief Operating Officer & Executive Vice President at Innate Pharma SA. He started this position in 2024.
Dr. Morel has an undergraduate degree from École normale supérieure Paris-Saclay and a doctorate degree from Université d'Aix-Marseille.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
INNATE PHARMA SA CLASS A 0,46 % | 30/03/2026 | 432.692 ( 0,46 % ) | 801 410 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| INNATE PHARMA | Director de Operaciones | 04/01/2024 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Innate Pharma SA
 Innate Pharma SA Pharmaceuticals: MajorHealth Technology Develops therapeutic antibodies that harness the immune system to improve cancer treatment and clinical outcomes | Health Technology |
École normale supérieure Paris-Saclay
 École normale supérieure Paris-Saclay Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Université d'Aix-Marseille
 Université d'Aix-Marseille Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
